SUMMARY
Risks of food fraud have been exacerbated by ongoing supply-chain shortages and reduced regulatory oversight caused by the COVID19 pandemic. Since food fraud cases involve adulterants that are deliberately disguised, resulting poisonings are especially difficult to investigate and treat. We encountered a near-fatal poisoning with “weight-loss candlenuts” that are readily available online. We leveraged state-of-the-art high-resolution mass spectrometry (HRMS) and discovered that commonly used spectral libraries and toxin/poison standards panels do not contain the materials needed to identify the causative agents of this nearly lethal poisoning. By building new methods, we ultimately found ‘Nuez de la India’ contain high levels of uncommon cardiac glycosides, while deploying HRMS as a novel ‘chemical fingerprinting’ tool revealed them to be mislabeled yellow oleander seeds. Our work presents a rapid investigative strategy to empower future investigations, and provides guiding principles to food safety programs for treating, and indeed preventing, these potentially fatal poisonings that are increasing worldwide.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
We are grateful to CDC for their support through the LRN-C network, FDA for helpful discussions and their support through the FERN network, EPA for a ROAR collaboration on HRMS method development for non-targeted analysis, and AB Sciex for technical and method support. We also extend our sincere appreciation to the Association of Public Health Laboratories for funding that supported F.G. as an APHL/CDC Informatics Fellow, and for competitively funding our high-resolution mass spectrometer purchase.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript.
